- Home
- GLUE vs VRTS Comparison
GLUE vs VRTS Comparison
Compare GLUE & VRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLUE | VRTS |
|---|---|---|
| Founded | 2019 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | GLUE | VRTS |
|---|---|---|
| Price | $13.42 | $167.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | $32.00 | ★ $158.00 |
| AVG Volume (30 Days) | ★ 1.5M | 101.5K |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 6.68% |
| EPS Growth | N/A | ★ 18.24 |
| EPS | N/A | ★ 7.72 |
| Revenue | ★ $123,672,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.45 | $1.66 |
| P/E Ratio | $72.42 | ★ $21.65 |
| Revenue Growth | ★ 63.54 | N/A |
| 52 Week Low | $4.68 | $121.61 |
| 52 Week High | $25.77 | $203.61 |
Technical Indicators
Market Signals| Indicator | GLUE | VRTS |
|---|---|---|
| Relative Strength Index (RSI) | 31.76 | 56.16 |
| Support Level | $13.95 | $161.58 |
| Resistance Level | $16.66 | $170.93 |
| Average True Range (ATR) | 0.64 | 3.00 |
| MACD | 0.06 | -0.48 |
| Stochastic Oscillator | 23.36 | 53.22 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About VRTS Virtus Investment Partners Inc.
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.